General Toxicity Notes
Require careful titration of dose according to clinical response.
Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
0.8-1.6/No data
Plasma Protein Binding %
5-8
Volume Of Distribution L/Kg
0.9-1.6
Dose For Normal Renal Function
250-500 mg bid
Second Dose
Second Dose: to 8 g q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50-100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50-100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984; 7: 35-49. [PMID: 6367973] / Robertson DR, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989; 28: 61-9. [PMID: 2775615]
Toxicity Notes
Active and inactive metabolites excreted in urine. Active metabolites with long T1/2 in ESRD.